Investors

Press Releases

Press Releases

Sep 14, 2020

Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Sep 09, 2020

Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors

Aug 27, 2020

Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

Aug 25, 2020

Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Aug 20, 2020

Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

Jul 09, 2020

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

Jun 11, 2020

Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

Jun 03, 2020

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis

Mar 12, 2020

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

Feb 05, 2020

Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation

Investor Contact

Bruce Jacobs
Chief Financial Officer
investors@kymeratx.com
+1 857.285.5300

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+ 1 339.970.2843

Media Contact

media@kymeratx.com

Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
+1 202.930.4762

Sign Up for Email Alerts